BioSpace News Archive

Seoul Viosys, a leading compound semiconductor solution provider, announced that it has developed an optimal module designed to sterilize 99.9% of the coronavirus in 3 seconds using “Violeds”, a UV LED technology, and started mass production.

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase stimulators for the treatment of serious and orphan diseases, announced that Company management will be participating in several upcoming September 2020 investor conferences

Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, announced two presentations for its TransCon PTH program in adult hypoparathyroidism at the 22nd European Congress of Endocrinology 2020, taking place online September 5–9, 2020.

Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced that Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the Citi 15th Annual BioPharma Virtual Conference on Thursday, September 10 at 2:25 p.m. ET.

Calithera Biosciences, Inc., a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, announced that the company will participate in four upcoming virtual healthcare investor conferences.

AbbVie and I-Mab to collaborate on development and commercialization of I-Mab’s highly differentiated anti-CD47 monoclonal antibody lemzoparlimab (TJC4)

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced that its management is scheduled to virtually participate in the following upcoming investor conferences

Bruker Corporation announced it will participate in the 2020 Wells Fargo Virtual Healthcare Conference.

Plenity (Gelesis100) is an orally administered, non-stimulant, non-systemic aid in weight management based on proprietary hydrogel technology with a highly favorable safety and efficacy profile demonstrated in clinical studies Plenity is currently available in the U.S. in limited release with a full launch in 2021 BOSTON--( BUSINESS WIRE )-- Gelesis, a biotechnology company developing a novel hydrogel platform technology to treat overweigh

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conferences: Citi’s 15 th Annual BioPharma Virtual Conference Panel: Innovation in Cell Therapy Date: Wednesday, September 9, 2020 Time: 3:20 p.m. ET Wells Fargo 2020 Virtual Healthcare Conference Fireside Chat Date: Thursday, September 10, 2020 Time: 10:40 a.m. ET Morgan Stanl